Connection

MENASHE BAR ELI to Animals

This is a "connection" page, showing publications MENASHE BAR ELI has written about Animals.
Connection Strength

0.841
  1. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 2014 Jan; 27(1):19-36.
    View in: PubMed
    Score: 0.020
  2. Crossing the junction in the gap of melanoma brain metastasis. Pigment Cell Melanoma Res. 2013 Jul; 26(4):435-7.
    View in: PubMed
    Score: 0.020
  3. Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev. 2012 Dec; 31(3-4):621-32.
    View in: PubMed
    Score: 0.019
  4. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012 Nov 15; 72(22):5757-66.
    View in: PubMed
    Score: 0.019
  5. PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res. 2011 Nov 01; 71(21):6561-6.
    View in: PubMed
    Score: 0.018
  6. Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res. 2011 May 15; 71(10):3494-504.
    View in: PubMed
    Score: 0.017
  7. Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc Natl Acad Sci U S A. 2011 Jan 11; 108(2):626-31.
    View in: PubMed
    Score: 0.017
  8. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol. 2011 Feb; 185(2):693-700.
    View in: PubMed
    Score: 0.017
  9. Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol. 2011 Apr; 21(2):83-8.
    View in: PubMed
    Score: 0.017
  10. CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One. 2010 Aug 27; 5(8):e12452.
    View in: PubMed
    Score: 0.016
  11. Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem. 2009 Sep 18; 284(38):26194-206.
    View in: PubMed
    Score: 0.015
  12. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol. 2008 Dec; 173(6):1839-52.
    View in: PubMed
    Score: 0.015
  13. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008 Nov 01; 68(21):9078-86.
    View in: PubMed
    Score: 0.015
  14. Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther. 2008 Jul; 7(7):997-1003.
    View in: PubMed
    Score: 0.014
  15. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 01; 14(5):1478-86.
    View in: PubMed
    Score: 0.014
  16. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood. 2008 Mar 01; 111(5):2904-8.
    View in: PubMed
    Score: 0.014
  17. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev. 2007 Dec; 26(3-4):359-71.
    View in: PubMed
    Score: 0.014
  18. The HOG-GLI face of melanoma. Pigment Cell Res. 2007 Oct; 20(5):341-2.
    View in: PubMed
    Score: 0.013
  19. Searching for the Achilles' heel of melanoma cells: new treatment modalities. Pigment Cell Melanoma Res. 2008 Oct; 21(5):505-6.
    View in: PubMed
    Score: 0.013
  20. ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res. 2007 Jun 01; 67(11):5258-66.
    View in: PubMed
    Score: 0.013
  21. Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene. 2007 Jun 14; 26(28):4049-58.
    View in: PubMed
    Score: 0.013
  22. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther. 2007 Feb; 14(4):316-23.
    View in: PubMed
    Score: 0.013
  23. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res. 2006 Oct; 19(5):395-405.
    View in: PubMed
    Score: 0.013
  24. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem. 2006 Feb 03; 281(5):2911-22.
    View in: PubMed
    Score: 0.012
  25. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res. 2005 Feb 01; 65(3):692-7.
    View in: PubMed
    Score: 0.011
  26. Construction and expression of intracellular anti-ATF-1 single chain Fv fragment: a modality to inhibit melanoma tumor growth and metastasis. Methods. 2004 Oct; 34(2):233-9.
    View in: PubMed
    Score: 0.011
  27. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol. 2004 Jun 01; 22(11):2092-100.
    View in: PubMed
    Score: 0.011
  28. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem. 2004 May 07; 279(19):19683-90.
    View in: PubMed
    Score: 0.010
  29. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004 Feb; 122(2):400-5.
    View in: PubMed
    Score: 0.010
  30. Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):631-8.
    View in: PubMed
    Score: 0.010
  31. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res. 2003 Dec 15; 9(17):6560-6.
    View in: PubMed
    Score: 0.010
  32. Sequence-based discovery of a synthetic peptide inhibitor of caspase 6. Apoptosis. 2003 Aug; 8(4):371-6.
    View in: PubMed
    Score: 0.010
  33. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res. 2003 Aug 01; 9(8):3167-75.
    View in: PubMed
    Score: 0.010
  34. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ. 2003 May; 10(5):558-69.
    View in: PubMed
    Score: 0.010
  35. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis. 2003; 20(3):251-63.
    View in: PubMed
    Score: 0.010
  36. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res. 2002 Nov; 8(11):3584-91.
    View in: PubMed
    Score: 0.010
  37. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 01; 62(17):5106-14.
    View in: PubMed
    Score: 0.009
  38. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther. 2002 Sep-Oct; 1(5):459-65.
    View in: PubMed
    Score: 0.009
  39. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul; 161(1):125-34.
    View in: PubMed
    Score: 0.009
  40. Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells. Mol Cell Biol. 2001 Aug; 21(15):4856-67.
    View in: PubMed
    Score: 0.009
  41. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene. 2001 Jun 07; 20(26):3363-75.
    View in: PubMed
    Score: 0.009
  42. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res. 2001 Apr; 14(2):78-85.
    View in: PubMed
    Score: 0.009
  43. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol Cell Biochem. 2000 Sep; 212(1-2):19-28.
    View in: PubMed
    Score: 0.008
  44. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene. 2000 May 18; 19(22):2721-30.
    View in: PubMed
    Score: 0.008
  45. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res. 1999 Jul; 19(7):697-703.
    View in: PubMed
    Score: 0.008
  46. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology. 1999; 67(1):12-8.
    View in: PubMed
    Score: 0.007
  47. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev. 1999; 18(3):377-85.
    View in: PubMed
    Score: 0.007
  48. Molecular changes in human melanoma metastasis. Histol Histopathol. 1998 10; 13(4):1225-31.
    View in: PubMed
    Score: 0.007
  49. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem. 1998 Sep 18; 273(38):24884-90.
    View in: PubMed
    Score: 0.007
  50. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 1998 Aug 03; 17(15):4358-69.
    View in: PubMed
    Score: 0.007
  51. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem. 1998 Jun 26; 273(26):16501-8.
    View in: PubMed
    Score: 0.007
  52. Molecular mechanisms of melanoma metastasis. J Cell Physiol. 1997 Nov; 173(2):275-8.
    View in: PubMed
    Score: 0.007
  53. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene. 1997 Oct 23; 15(17):2069-75.
    View in: PubMed
    Score: 0.007
  54. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 1997 Oct; 151(4):1105-13.
    View in: PubMed
    Score: 0.007
  55. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 1997 Jun 01; 57(11):2295-303.
    View in: PubMed
    Score: 0.007
  56. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene. 1996 Dec 05; 13(11):2339-47.
    View in: PubMed
    Score: 0.006
  57. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res. 1996 Dec; 2(12):1969-79.
    View in: PubMed
    Score: 0.006
  58. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 1996 Jan 15; 56(2):254-8.
    View in: PubMed
    Score: 0.006
  59. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene. 1995 Oct 05; 11(7):1399-402.
    View in: PubMed
    Score: 0.006
  60. Wild-type p53 regulates its own transcription in a cell-type specific manner. DNA Cell Biol. 1995 Sep; 14(9):759-66.
    View in: PubMed
    Score: 0.006
  61. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res. 1995 Aug 15; 55(16):3669-74.
    View in: PubMed
    Score: 0.006
  62. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21.
    View in: PubMed
    Score: 0.006
  63. Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J Interferon Cytokine Res. 1995 Jul; 15(7):655-65.
    View in: PubMed
    Score: 0.006
  64. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother. 1994 Oct; 39(4):231-8.
    View in: PubMed
    Score: 0.005
  65. The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. Int J Cancer. 2015 Mar 15; 136(6):1296-307.
    View in: PubMed
    Score: 0.005
  66. Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res. 1994 Sep-Oct; 14(5A):1759-65.
    View in: PubMed
    Score: 0.005
  67. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene. 1994 Jul; 9(7):1877-83.
    View in: PubMed
    Score: 0.005
  68. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 2004 May 15; 64(10):3479-85.
    View in: PubMed
    Score: 0.005
  69. Monocyte subpopulations in angiogenesis. Cancer Res. 2014 Mar 01; 74(5):1287-93.
    View in: PubMed
    Score: 0.005
  70. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest. 2013 Jun; 123(6):2703-18.
    View in: PubMed
    Score: 0.005
  71. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 2013 Jul 15; 73(14):4383-94.
    View in: PubMed
    Score: 0.005
  72. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
    View in: PubMed
    Score: 0.005
  73. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res. 1993 Feb; 3(1):35-41.
    View in: PubMed
    Score: 0.005
  74. Src activation by ?-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4:1403.
    View in: PubMed
    Score: 0.005
  75. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther. 2011 May 01; 11(9):839-45.
    View in: PubMed
    Score: 0.004
  76. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 Nov 12; 285(46):35462-70.
    View in: PubMed
    Score: 0.004
  77. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010 Sep; 12(9):748-54.
    View in: PubMed
    Score: 0.004
  78. The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 2010 Apr 01; 70(7):2571-4.
    View in: PubMed
    Score: 0.004
  79. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009 Oct 01; 69(19):7538-47.
    View in: PubMed
    Score: 0.004
  80. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 2008 Oct 15; 68(20):8419-28.
    View in: PubMed
    Score: 0.004
  81. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 2008 Sep; 180(3):1146-53.
    View in: PubMed
    Score: 0.004
  82. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia. 2008 May; 10(5):489-500.
    View in: PubMed
    Score: 0.004
  83. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 2008 Jul; 7(7):1098-103.
    View in: PubMed
    Score: 0.003
  84. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 05; 100(5):359-72.
    View in: PubMed
    Score: 0.003
  85. Association in the expression of Kirsten-ras oncogene and the major histocompatibility complex class I antigens in fibrosarcoma tumor cell variants exhibiting different metastatic capabilities. Cancer Res. 1987 May 15; 47(10):2553-7.
    View in: PubMed
    Score: 0.003
  86. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007 Jan; 6(1):277-85.
    View in: PubMed
    Score: 0.003
  87. Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biol Ther. 2006 Dec; 5(12):1588-99.
    View in: PubMed
    Score: 0.003
  88. ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics. Cancer. 2006 May 15; 106(10):2295-308.
    View in: PubMed
    Score: 0.003
  89. Progression elevated gene-3 (PEG-3) induces pleiotropic effects on tumor progression: modulation of genomic stability and invasion. J Cell Physiol. 2005 Jan; 202(1):135-46.
    View in: PubMed
    Score: 0.003
  90. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 2004 Oct 15; 64(20):7361-9.
    View in: PubMed
    Score: 0.003
  91. Focus on bladder cancer. Cancer Cell. 2004 Aug; 6(2):111-6.
    View in: PubMed
    Score: 0.003
  92. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004 Mar; 3(3):279-90.
    View in: PubMed
    Score: 0.003
  93. Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 2004 Jan 01; 64(1):146-51.
    View in: PubMed
    Score: 0.003
  94. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003 Jul; 9(7):2786-97.
    View in: PubMed
    Score: 0.003
  95. Expression of a methotrexate-resistant dihydrofolate reductase gene by transformed hematopoietic cells of mice. Somatic Cell Genet. 1983 Jan; 9(1):55-67.
    View in: PubMed
    Score: 0.002
  96. ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells. J Biol Chem. 2002 Jun 14; 277(24):21325-31.
    View in: PubMed
    Score: 0.002
  97. Insertion of drug resistance genes in animals. J Cell Physiol Suppl. 1982; 1:213-7.
    View in: PubMed
    Score: 0.002
  98. The progeny of a single progenitor cell can develop characteristics of either a tissue or an alveolar macrophage. Blood. 1981 Jan; 57(1):95-8.
    View in: PubMed
    Score: 0.002
  99. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000 May; 6(5):2104-19.
    View in: PubMed
    Score: 0.002
  100. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000 Apr 15; 60(8):2290-9.
    View in: PubMed
    Score: 0.002
  101. Age-dependent macrophage functions in New Zealand black mice. Cell Immunol. 1979 Jul; 45(2):309-17.
    View in: PubMed
    Score: 0.002
  102. Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res. 1998 Jul 01; 58(13):2733-6.
    View in: PubMed
    Score: 0.002
  103. Studies on the relationships between the immunogenicity and catabolism of antigens and their binding to the surface of macrophages. Eur J Immunol. 1976 Nov; 6(11):789-94.
    View in: PubMed
    Score: 0.002
  104. The effect of macrophage hydrolytic enzyme levels on the uptake and degradation of antigen and immune complexes. J Reticuloendothel Soc. 1975 Dec; 18(6):317-28.
    View in: PubMed
    Score: 0.001
  105. Proceedings: Uptake and degradation of Ag and Ag Ab complexes by differently stimulated macrophages. Isr J Med Sci. 1975 Dec; 11(12):1379.
    View in: PubMed
    Score: 0.001
  106. Evolutionary conservation of brain Thy-1 glycoprotein in vertebrates and invertebrates. Dev Comp Immunol. 1985; 9(3):497-509.
    View in: PubMed
    Score: 0.001
  107. NK sensitivity, H-2 expression and metastatic potential: analysis of H-2Dk gene transfected fibrosarcoma cells. J Immunogenet. 1989 Aug-Oct; 16(4-5):305-13.
    View in: PubMed
    Score: 0.001
  108. The relationship between MHC antigen expression and metastasis. Adv Cancer Res. 1989; 53:89-115.
    View in: PubMed
    Score: 0.001
  109. Influence of H-2K transfection on susceptibility of fibrosarcoma tumor cells to natural killer (NK) cells. Immunol Lett. 1988 Mar; 17(3):261-5.
    View in: PubMed
    Score: 0.001
  110. The immunobiology of metastatic processes: analysis of NK sensitivity and the metastatic potential of H-2 gene transfected fibrosarcoma cells. Nat Immun Cell Growth Regul. 1988; 7(3):155-62.
    View in: PubMed
    Score: 0.001
  111. NK sensitivity, H-2, c-K-ras proto-oncogene expression and metastases: analysis of the metastatic potential of H-2 gene transfected fibrosarcoma cells. Adv Exp Med Biol. 1988; 233:151-60.
    View in: PubMed
    Score: 0.001
  112. Expression of ki-ras oncogene in tumor cell variants exhibiting different metastatic capabilities. Int J Cancer. 1985 Feb 15; 35(2):227-30.
    View in: PubMed
    Score: 0.001
  113. Insertion of new genetic information into bone marrow cells of mice: comparison of two selectable genes. Ann N Y Acad Sci. 1982 Dec 10; 397:272-80.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.